3 Stocks Near 52-Week Highs Worth Selling

Are Allergan, Cavco Industries, and GW Pharmaceuticals sells or belles? You be the judge!

Mar 13, 2014 at 4:03PM

It appears that not even geopolitical concerns and threats of a global growth slowdown can keep the broad-based S&P 500 from running to fresh all-time highs. For skeptics like me, that's an opportunity to see whether companies have earned their current valuations.

Keep in mind that some companies deserve their current valuations. International telecom giant and personal portfolio holding Orange (NYSE:ORAN) saw its shares touch a fresh 52-week high earlier this week after the company surprised Wall Street with better-than-expected international growth. For the full year, Orange's sales fell 4.5%, hurt in part by unfavorable regulatory measures in France. However, Orange delivered robust sales growth of 4.4% in Spain, and 4.7% growth in Africa and the Middle East. Even more encouraging, it reached its goal of one million 4G broadband customers in France. If Orange can continue to focus on these higher-margin data plans in France while also growing its rest-of-world business, then there's a good chance it can head even higher.

Still, other companies might deserve a kick in the pants. Here's a look at three that could be worth selling.

Don't get teary-eyed
Practically the entire health care industry is on fire, with venture capital flowing in from all angles. Even big pharma has been able to participate in this rally in a big way. However, not all rallies in the big pharma space have made sense.

Take Allergan (NYSE:AGN) for example. Allergan shares have found solid footing since the company reported a 12% increase in revenue to $6.2 billion in fiscal 2013. Leading to this jump was a 43% increase in skin care revenue, a 13% jump in Botox and other neuromodulators, and a 23% rise in facial aesthetics revenue. All told, it would appear to be a pretty solid year for Allergan.

However, all is not perfectly well with Allergan. To begin with, the company purchased MAP Pharmaceuticals for just shy of $1 billion last year to get a hold of its inhaled migraine medication levadex, which, based on its clinical data, seemed to have better than a 50-50 shot to receive FDA approval. But that approval has yet to arrive due to manufacturing concerns from the FDA that have resulted in two complete response letters. As of now, Allergan's purchase has been for naught. 

Allergan also suffered a big blow in its efforts to diversify its eye-care pipeline when in May of last year it reported disappointing results from its mid-stage study of DARPin. The drug had been expected to compete with Regeneron Pharmaceuticals' Eylea, but that looks like a pipe dream at present, with its future in doubt.

There's also the fact that Allergan's growth is beginning to slow, with high single-digit revenue increases expected this year and next. While not bad, that could be a bit excessive considering that Allergan is valued at 21 times forward earnings and offers very little in the way of shareholder incentives, with just a $0.20 annual dividend.

I believe there are far better pharmaceutical options available and would suggest exiting Allergan here.

The wrong type of mobile
Speaking of valuations that are getting a bit out of hand, mobile-home manufacturer Cavco Industries (NASDAQ:CVCO) has crossed my radar in a bad way.

The manufactured-home developer has surged in recent months since it acquired the remaining non-controlling interest in its subsidiaries during the second quarter, which helped push revenue up 21% and allowed its net income to nearly double in the third quarter. I certainly wouldn't take anything away from Cavco, which has benefited from record low lending rates and a cost-conscious consumer.

However, investors could be set up for some year-over-year growth disappointments once we get beyond these next three quarters following the purchase of its remaining non-controlling interest, and once the Federal Reserve is done pumping money into the economy via QE3. I've long contended that the U.S. consumer has been spoiled by historically low lending rates, and any bump higher in interest rates, which seems likely from a reduction in U.S. long-term Treasury purchases, seems as if it'll hurt housing demand in all forms.

Cavco also benefited from lower tax rates this past quarter, which have a tendency to fluctuate. The translation is that you should take its doubling in net income with a grain of salt, and expect its effective tax rate to continue to vacillate on a quarterly basis.

Simply put, at 31 times forward earnings Cavco's risk-versus-reward profile is far too skewed toward the risk side for my liking. With interest rates likely to rise and tough year-over-year comparisons around the corner, Cavco is going to need to execute perfectly if it hopes to maintain its current valuation.

A smoking-hot trade
There is perhaps no hotter trader right now than the medical marijuana bandwagon. There are 20 states in the U.S. that now allow consumers to use medical marijuana for select ailments, and even two states -- Washington and Colorado -- that have approved marijuana for recreational purposes in one's own home. But therein lies the rub: Everyone thinks it's a great idea.

Usually one of the telltale signs of a possible top is a trade that everyone is betting on; and you'd have to look pretty hard right now to find any investor who doesn't see marijuana's growth potential as explosive. That thinking has caused investors to pile into GW Pharmaceuticals (NASDAQ:GWPH), a U.K.-based biopharmaceutical company that's utilizing cannabinoids extracted from the cannabis plant to develop potential therapies for a number of ailments.

GW Pharmaceuticals currently has one product on the market in select European countries known as Sativex. Combining CBD and THC, this drug is designed to reduce the effects of spasticity in multiple sclerosis patients while minimizing the "high" often associated with smoking marijuana.

Obviously, having an approved product validates the company's platform. But can it really take off? I believe it has the potential to, but investors are pricing the company as if Sativex sales are soaring when in reality they aren't. As of the latest quarter, GW Pharma only produced $12.4 million in revenue, which would extrapolate out to around $50 million in revenue for the full-year. Yet GW Pharma is currently valued north of $1.2 billion and is still losing money.

If GW Pharma is able get Sativex approved in the U.S. or can bring more than just one product to market, then perhaps I'd be able to entertain a $1 billion valuation, but until that happens, its current sales growth simply doesn't merit this.

You'd be foolish to consider selling this top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams owns shares of Orange, but has no material interest in any other companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Orange. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers